Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?

United European Gastroenterology Journal

Volumn 2, Issue 5, 2014, Pages 374-382

  Menon, Shyam ^a   Nightingale, Peter ^b   Trudgill, Nigel ^c  

^a ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c SANDWELL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Barrett s oesophagus; Hormone replacement therapy; Oesophageal adenocarcinoma; Oesophageal cancer; Oesophageal squamous cell carcinoma; Reflux oesophagitis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; STEROID; THEOPHYLLINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASTHMA; BARRETT ESOPHAGUS; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; TREATMENT DURATION;

EID: 85006198790     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614543736     Document Type: Article

References (35)

1. Corley DA and Buffler PA. Oesophageal and gastric adenocarcinomas: Analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 2001; 30: 1415–1425.
2. Derakshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58: 16–23.
3. Ashcroft GS, Greenwell-Wild T, Horan MA, et al. Topical estrogen accelerates cutaneous would healing in aged humans associated with an altered inflammatory response. Am J Path 1999; 155: 1137–1146.
4. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-b1 levels. Nat Med 1997; 3: 1209–1215.
5. Naef AP, Savary M and Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition: Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975; 70: 826–834.
6. Haggitt RC, Tryzelaar J, Ellis FH, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. Am J Clin Pathol 1978; 70: 1–5.
7. Lindblad M, Garcia Rodriguez LA, Chandanos E, et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006; 94: 136–141.
8. Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and metaanalysis. Int J Cancer 2011; 130: 2387–2396.
9. GarciaRodriguez LA and Gutthann SP. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419–425.
10. Jick H, Jick SS and Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766–768.
11. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Safety 1992; 1: 347–349.
12. Menon S, Jayasena H, Nightingale P, et al. The influence of age and gender on endoscopic findings of gastro-oesophageal reflux disease: An endoscopy database study. Eur J Gastroenterol Hepatol 2011; 23: 389–395.
13. Grossman C. Possible underlying mechanisms of sexual dimorphisms in the immune response, fact and hypothesis. J Steroid Biochem 1989; 34: 241–251.
14. Olsen NJ and Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17: 369–384.
15. Cocchiara R, Albreggiani G, Di Trapani A, et al. Modulation of rat peritoneal mast cell and human basophil histamine release by oestrogens. Int Arch Allergy Appl Immunol 1990; 93: 192–197.
16. Gulshan S, Mc Cruden and Stimson WH. Oestrogen receptors in macrophages. Scand J Immunol 1990; 31: 691–697.
17. Benten WP, Stephan C, Lieberherr F, et al. Estradiol signalling via sequestrable surface receptors. Endocrinology 2001; 142: 1669–1677.
18. Mao A, Pharkova-Vatchkova V, Hardy J, et al. Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J Immunol 2005; 175: 5146–5151.
19. Suzuki T, Shimizu T, Yu HP, et al. Salutary effects of 17-beta estradiol on T cell signalling and cytokine production after trauma-hemorrhage are mediated primarily via estrogen receptor alpha. Am J Physiol Cell Physiol 2007; 292: C2103–C2111.
20. Ito I, Hayashi T, Yamada K, et al. Physiological concentration of estradiol inhibits polymorphonuclear leucocyte chemotaxis via a receptor mediated system. Life Sci 1995; 56: 2247–2253.
21. Ferry G, Lonchampt M, Pennel L, et al. Activation of MMP-9 by neutrophil elastase in an in vivo modal of acute lung injury. FEBS Lett 1997; 402: 111–115.
22. Masaka T, Lijima K, Endo H, et al. Gender differences in oesophageal mucosal injury in a reflux oesophagitis model of rats. Gut 2013; 62: 6–14.
23. Jacobson BC, Moy B, Colditz GA, et al. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med 2008; 168: 1798–1804.
24. Jacobson BC, Somers SC, Fuchs CS, et al. Barrett’s oesophagus body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 2340–2348.
25. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290: 66–72.
26. Nilsson M, Lundegardh G, Carling L, et al. Barrett’s oesophagus, body mass and reflux oesophagitis: An oestrogen- dependent association? Scand J Gastroenterol 2002; 37: 626–630.
27. Fisher RS, Robert GS, Grawski CJ, et al. Altered lower esophageal sphincter function during early pregnancy. Gastroenterology 1978; 74: 1233–1237.
28. Hirsch DP, Holloway RH, Tytgat GN, et al. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998; 115: 1374–1380.
29. Konturek JW, Thor P, Lukaszyk A, et al. Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol 1997; 48: 201–209.
30. De Man G, Pleckmans PA, Boeckxstaens GE, et al. The role of nitric oxide in inhibitory non-adrenergic noncholinergic neurotransmission in the canine lower oesophageal sphincter. Br J Pharmacol 1991; 103: 1092–1096.
31. Lagergren J, Bergstro¨m R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–831.
32. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388–396.
33. Beral V, Reeves G, Green J, et al. The effect of hormone replacement therapy on breast and other cancers. In: Critchley H, Gebbie A and Beral V (eds) Menopause and Hormone Replacement. London: RCOG Press, pp. 136–150.
34. Beral V, Banks E, Reeves G, et al. Use of hormone replacement therapy and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4: 191–215.
35. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.